Top Stories
No archived items in this category yet.
Top Headlines
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…
STAT+: RFK Jr.’s second year: Vacancies, not vaccines
Assessing the health secretary's biggest challenges, and a look at new rules that inject politics into the NIH.
STAT+: AI titans push Congress for DNA safeguards
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
STAT+: Utah Medical Board scolded for going rogue with AI criticism
In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law
Scientists uncover a new hiding spot for HIV
An Ebola update, Trump to strip job protections of NIH officials, and more health news from Morning Rounds
ScionHealth sends 8 community hospitals to Lifepoint Health
The deal between the nationwide sister systems grows Lifepoint Health to a network of 68 community hospital campuses, and allows ScionHealth to increase focus on its core business of specialty hospital services.
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.
Thyme Care expands cancer survivorship program to provide longitudinal support
Thyme Care has expanded its cancer survivorship program, called Next Chapter Care, to provide a personalized, longitudinal approach to survivorship support.
Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
“One of the cancer community’s worst fears is coming to pass,” writes Gwen Nichols of Blood Cancer United.
STAT+: After hospitals, patients get a turn to bring AI into the doctor’s office
Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them as diligent note-takers for patients.